Alpha-adrenergic receptor stimulant ophthalmic composition and application thereof

By combining α-adrenaline receptor agonist and M choline receptor agonist in ophthalmic preparations, the problem of ocular surface damage caused by preservatives in existing ophthalmic preparations is solved, and the stability and patient compliance of the preparation are improved by simplifying the formulation, achieving multiple efficacy and high safety ophthalmic compositions.

CN119700989APending Publication Date: 2025-03-28SUZHOU PRO HEAL PHARM TECH CO LTD
3 Cites 0 Cited by

Patent Information

Application Number
CN202311275732.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-09-28
Publication Date
2025-03-28

AI Technical Summary

Technical Problem

Existing ophthalmic preparations mostly contain preservatives, which may cause eye surface damage after long-term use. The formulation of the preparation is complex, and the stability and patient compliance are insufficient.

Method used

An ophthalmic composition is provided, which comprises an alpha-adrenergic receptor agonist and an M choline receptor agonist, and is free of other auxiliary materials such as preservatives, buffers, complexing agents and excipients, and is prepared by a simple preparation method.

Benefits of technology

The composition has a long holding time, reaching 10 hours, which can quickly eliminate conjunctival congestion, reduce visual fatigue, and has good therapeutic effects on preventing and treating a variety of eye diseases. It is also highly safe and has few side effects, and is suitable for long-term use.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to an alpha-adrenergic receptor agonist ophthalmic composition and application thereof. The composition comprises an alpha-adrenergic receptor agonist and an M choline receptor agonist. The ophthalmic composition provided by the invention can meet the requirements of different patients for improving short-distance vision and long-distance vision, and has a relatively long retention time up to 10 hours. In addition, the composition provided by the invention can quickly eliminate conjunctival congestion and asthenopia, and has a good curative effect on preventing and treating eye diseases such as presbyopia, ocular hypertension, xerophthalmia, myopia, hyperopia, strabismus, astigmatism, photophobia or glaucoma.
Need to check novelty before this filing date? Find Prior Art